H. Lundbeck A/S operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares H. Lundbeck A/S with three other
pharmaceutical manufacturers in Europe:
Hikma Pharmaceuticals PLC
of the United Kingdom
sales of £1.45 billion [US$1.89 billion]
of which 40%
was Injectable Pharmaceuticals),
Stada Arzneimittel AG
(2.14 billion Euro [US$2.47 billion]
of which 60%
was Generics), and
based in France
(1.67 billion Euro [US$1.93 billion]
of which 76%
was Specialty Care).
H. Lundbeck A/S reported sales of 15.63 billion Danish Kroner (US$2.43 billion)
December of 2016.
increase of 7.1%
versus 2015, when the company's sales were 14.59 billion Danish Kroner.
The sales level in 2016 was fairly close to the level five years ago: in 2011, H. Lundbeck A/S had sales
of 16.01 billion Danish Kroner.
Sales of Brintellix/trintellix saw an increase
that was more than double the company's growth rate: sales were up
75.7% in 2016, from
629.00 million Danish Kroner to 1.11 billion Danish Kroner.
H. Lundbeck A/S also saw significant increases in sales in
Onfi (up 37.1% to 2.41 billion Danish Kroner)
Sabril (up 36.2% to 1.34 billion Danish Kroner)
Abilify Maintena (up 66.5% to 1.11 billion Danish Kroner)
Not all segments of H. Lundbeck A/S experienced an increase in sales in 2016:
sales of Xenazine fell 28.6% to 1.57 billion Danish Kroner.
H. Lundbeck A/S also experienced decreases in sales in
Other Pharmaceuticals (down 6.3% to 2.99 billion Danish Kroner)
Cipralex (down 2.8% to 2.52 billion Danish Kroner)